Total di-22:6-BMP levels were measured using a mass spectrometry–based assay and were normalized with creatinine concentrations (ng mg -1). Mean (±s.e.m.) values were plotted against timepoints of sample collection (baseline and months 1, 2, 3, 6, 9 and 12). Percent of total di-22:6-BMP levels relative to baseline is shown. For BMP species, an increase of BMP levels compared to baseline was observed. The increase of BMP was sustained until month 12 for the low-dose cohort and until month 3 for the mid-dose cohort. Data plots of individual patients are provided in Extended Data Fig. 6 . The increased BMP levels approached values measured in urine samples obtained from healthy human controls, which were measured as 50.4 ± 7.7 for di-22:6-BMP (mean ± s.e.m., n = 24).
